Evidence map›Paper›PMID 31788713›Full record

ArticleInternational ophthalmology2020

Intravitreal ranibizumab versus vitrectomy for recurrent vitreous haemorrhage after pars plana vitrectomy for proliferative diabetic retinopathy: a prospective study.

Irini Chatziralli, Eleni Dimitriou, George Theodossiadis, Evgenia Bourouki, Eleni Bagli, George Kitsos, Panagiotis Theodossiadis

Abstract read
PubMed Publisher
In one paragraph

Article in International ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Irini Chatziralli2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece. eirchat@yahoo.gr.
Eleni Dimitriou2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece.
George Theodossiadis2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece.
Evgenia Bourouki2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece.
Eleni BagliDepartment of Ophthalmology, University of Ioannina, Ioannina, Greece.
George KitsosDepartment of Ophthalmology, University of Ioannina, Ioannina, Greece.
Panagiotis Theodossiadis2nd Department of Ophthalmology, Attikon Hospital, National and Kapodistrian University of Athens, 1, Rimini street, 12462, Haidari, Greece.
National and Kapodistrian University of Athens · GRUniversity General Hospital Attikon · GRUniversity of Ioannina · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare prospectively intravitreal ranibizumab treatment and pars plana vitrectomy (PPV) in patients with recurrent vitreous haemorrhage (VH) due to proliferative diabetic retinopathy (PDR), who were previously treated with PPV.

methodsParticipants in this prospective study were 37 patients (37 eyes) with PDR, previously treated with PPV. All patients presented recurrent VH and were treated with either ranibizumab (n = 18) or PPV (n = 19). All participants were examined at week 2 post-treatment and every month thereafter for 1 year. Main outcomes were the need of PPV, the rate of recurrence of VH and the change in visual acuity by the end of the 12-month follow-up.

resultsAt month 12, there was statistically significant improvement in visual acuity in both groups compared to baseline, but the two groups did not differ regarding the change in visual acuity. In ranibizumab group, two patients presented recurrent VH during the follow-up and one patient needed PPV to clear the VH by month 12. In PPV group, two patients had mild recurrent VH, which cleared itself. No statistically significant difference was noticed regarding the rate of recurrent VH and the need of PPV between the two groups.

conclusionIntravitreal ranibizumab seems to be a safe and effective treatment alternative in patients with recurrent VH secondary to PDR, who had been previously treated with PPV.

Indexed as

Visual AcuityAgedAngiogenesis InhibitorsDiabetic RetinopathyFemaleFollow-Up StudiesHumansIntravitreal InjectionsMaleMiddle AgedProspective StudiesRanibizumabRecurrenceTreatment OutcomeVascular Endothelial Growth Factor AVitrectomyAngiogenesis InhibitorsRanibizumabVascular Endothelial Growth Factor AProliferative diabetic retinopathyRanibizumabVitrectomyVitreous haemorrhage

Identifiers

PMID31788713
OpenAlexW2990288604

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.